Marktanalyse - Poliomyelitis - Pipeline Review, H2 2016

Global Markets Direct
12.2016
85 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Poliomyelitis - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis — Pipeline Review, H2 2016, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 2, 5 and 7 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Poliomyelitis Overview 9

Therapeutics Development 10

Pipeline Products for Poliomyelitis - Overview 10

Pipeline Products for Poliomyelitis - Comparative Analysis 11

Poliomyelitis - Therapeutics under Development by Companies 12

Poliomyelitis - Therapeutics under Investigation by Universities/Institutes 14

Poliomyelitis - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Poliomyelitis - Products under Development by Companies 18

Poliomyelitis - Products under Investigation by Universities/Institutes 20

Poliomyelitis - Companies Involved in Therapeutics Development 21

Beijing Minhai Biotechnology Co Ltd 21

Beijing Tiantan Biological Products Co Ltd 22

Bharat Biotech International Ltd 23

Biken Inc 24

Bilthoven Biologicals BV 25

Biological E Ltd 26

Boryung Pharmaceutical Co Ltd 27

Codagenix Inc 28

Daiichi Sankyo Company Ltd 29

GlaxoSmithKline Plc 30

Grifols SA 31

Johnson & Johnson 32

Kaketsuken KK 33

LG Life Science LTD 34

Nanolek 35

Panacea Biotec Ltd 36

Sanofi Pasteur SA 37

Sentinext Therapeutics Sdn Bhd 38

Shantha Biotechnics Ltd 39

Taiga Biotechnologies Inc 40

Takeda Pharmaceutical Company Ltd 41

Poliomyelitis - Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Combination Products 43

Assessment by Target 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

(diphtheria + haemophilus influenzae [serotype B] + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

BVN-002 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

immune globulin (human) - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

ImmunoRx - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

IPVGVI-3000 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

KD-370 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

LBVC - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

LBVD - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

polio (virus like particle, bivalent) vaccine - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

polio [strain Sabin] vaccine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

polio vaccine - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

polio vaccine - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

polio vaccine - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

polio vaccine - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

polio vaccine - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

polio vaccine - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

poliomyelitis vaccine - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

TAK-195 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

VN-0105 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Poliomyelitis - Dormant Projects 80

Poliomyelitis - Discontinued Products 81

Poliomyelitis - Product Development Milestones 82

Featured News & Press Releases 82

Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate 82

Appendix 84

Methodology 84

Coverage 84

Secondary Research 84

Primary Research 84

Expert Panel Validation 84

Contact Us 84

Disclaimer 85





List of Tables

Number of Products under Development for Poliomyelitis, H2 2016 10

Number of Products under Development for Poliomyelitis - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2016 20

Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 21

Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2016 22

Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H2 2016 23

Poliomyelitis - Pipeline by Biken Inc, H2 2016 24

Poliomyelitis - Pipeline by Bilthoven Biologicals BV, H2 2016 25

Poliomyelitis - Pipeline by Biological E Ltd, H2 2016 26

Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 27

Poliomyelitis - Pipeline by Codagenix Inc, H2 2016 28

Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 29

Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H2 2016 30

Poliomyelitis - Pipeline by Grifols SA, H2 2016 31

Poliomyelitis - Pipeline by Johnson & Johnson, H2 2016 32

Poliomyelitis - Pipeline by Kaketsuken KK, H2 2016 33

Poliomyelitis - Pipeline by LG Life Science LTD, H2 2016 34

Poliomyelitis - Pipeline by Nanolek, H2 2016 35

Poliomyelitis - Pipeline by Panacea Biotec Ltd, H2 2016 36

Poliomyelitis - Pipeline by Sanofi Pasteur SA, H2 2016 37

Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016 38

Poliomyelitis - Pipeline by Shantha Biotechnics Ltd, H2 2016 39

Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H2 2016 40

Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 41

Assessment by Monotherapy Products, H2 2016 42

Assessment by Combination Products, H2 2016 43

Number of Products by Stage and Target, H2 2016 45

Number of Products by Stage and Route of Administration, H2 2016 47

Number of Products by Stage and Molecule Type, H2 2016 49

Poliomyelitis - Dormant Projects, H2 2016 80

Poliomyelitis - Discontinued Products, H2 2016 81





List of Figures

Number of Products under Development for Poliomyelitis, H2 2016 10

Number of Products under Development for Poliomyelitis - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 42

Assessment by Combination Products, H2 2016 43

Number of Products by Targets, H2 2016 44

Number of Products by Stage and Targets, H2 2016 44

Number of Products by Routes of Administration, H2 2016 46

Number of Products by Stage and Routes of Administration, H2 2016 46

Number of Products by Molecule Types, H2 2016 48

Number of Products by Stage and Molecule Types, H2 2016 48

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus